On the prevalence of vernal keratoconjunctivitis and current possibilities of treatment

The importance of vernal keratoconjunctivitis (vernal conjunctivitis, or vernal catarrh) is not so much due to its level of prevalence (today its occurrence amounts to 1.25-11.29 per 10 000 population of European countries), but rather to the severity of its clinical course. Especially significant i...

Full description

Saved in:
Bibliographic Details
Main Author: V. V. Brzheskiy
Format: Article
Language:Russian
Published: Real Time Ltd 2018-10-01
Series:Российский офтальмологический журнал
Subjects:
Online Access:https://roj.igb.ru/jour/article/view/126
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849394062673575936
author V. V. Brzheskiy
author_facet V. V. Brzheskiy
author_sort V. V. Brzheskiy
collection DOAJ
description The importance of vernal keratoconjunctivitis (vernal conjunctivitis, or vernal catarrh) is not so much due to its level of prevalence (today its occurrence amounts to 1.25-11.29 per 10 000 population of European countries), but rather to the severity of its clinical course. Especially significant is its tarsal form, which is complicated in 3-11 % of vernal keratoconjunctivitis patients by the development of corneal ulcers. Such patients are normally treated by antiallergic agents, which offer both antihistamine and mast cell-stabilizing action. Primarily, the medicines used are 0.1 % olopatadine and 0.025 % ketotifen, which can also reduce the activation of eosinophils and the production of pro-inflammatory cytokines. The therapy of resistant forms of the disease is successfully supplemented with instillations and / or ointment forms of glucocorticoids, cyclosporine-A, tacrolimus and mitomycin-C. Giant papillae that cause gravitational ptosis or are combined with the torpid current of the disease require surgical treatment. They are excised (or cryodestructed) with intraoperative treatment of the tarsal conjunctiva with 0.02 % mitomycin-C and subsequent instillations of cyclosporine-A. There is a need to further develop and introduce into clinical practice new pathogenetically oriented medicinal preparations which provide both relief of clinical symptoms of the disease and the prevention of its relapses. For citations: Brzheskiy V.V. On the prevalence of vernal keratoconjunctivitis and current possibilities of treatment. Russian ophthalmological journal. 2017; 10 (4): 74-81. doi: 10.21516/2072-0076-2017-10-4-74-81 (in Russian).
format Article
id doaj-art-86af72f3766f45dbbfab7a31afbb7902
institution Kabale University
issn 2072-0076
2587-5760
language Russian
publishDate 2018-10-01
publisher Real Time Ltd
record_format Article
series Российский офтальмологический журнал
spelling doaj-art-86af72f3766f45dbbfab7a31afbb79022025-08-20T03:40:11ZrusReal Time LtdРоссийский офтальмологический журнал2072-00762587-57602018-10-01104748110.21516/2072-0076-2017-10-4-74-81126On the prevalence of vernal keratoconjunctivitis and current possibilities of treatmentV. V. Brzheskiy0St. Petersburg State Pediatric Medical UniversityThe importance of vernal keratoconjunctivitis (vernal conjunctivitis, or vernal catarrh) is not so much due to its level of prevalence (today its occurrence amounts to 1.25-11.29 per 10 000 population of European countries), but rather to the severity of its clinical course. Especially significant is its tarsal form, which is complicated in 3-11 % of vernal keratoconjunctivitis patients by the development of corneal ulcers. Such patients are normally treated by antiallergic agents, which offer both antihistamine and mast cell-stabilizing action. Primarily, the medicines used are 0.1 % olopatadine and 0.025 % ketotifen, which can also reduce the activation of eosinophils and the production of pro-inflammatory cytokines. The therapy of resistant forms of the disease is successfully supplemented with instillations and / or ointment forms of glucocorticoids, cyclosporine-A, tacrolimus and mitomycin-C. Giant papillae that cause gravitational ptosis or are combined with the torpid current of the disease require surgical treatment. They are excised (or cryodestructed) with intraoperative treatment of the tarsal conjunctiva with 0.02 % mitomycin-C and subsequent instillations of cyclosporine-A. There is a need to further develop and introduce into clinical practice new pathogenetically oriented medicinal preparations which provide both relief of clinical symptoms of the disease and the prevention of its relapses. For citations: Brzheskiy V.V. On the prevalence of vernal keratoconjunctivitis and current possibilities of treatment. Russian ophthalmological journal. 2017; 10 (4): 74-81. doi: 10.21516/2072-0076-2017-10-4-74-81 (in Russian).https://roj.igb.ru/jour/article/view/126весенний кератоконъюнктивитраспространенностьпатогенезлечениеvernal keratoconjunctivitisprevalencepathogenesistreatment
spellingShingle V. V. Brzheskiy
On the prevalence of vernal keratoconjunctivitis and current possibilities of treatment
Российский офтальмологический журнал
весенний кератоконъюнктивит
распространенность
патогенез
лечение
vernal keratoconjunctivitis
prevalence
pathogenesis
treatment
title On the prevalence of vernal keratoconjunctivitis and current possibilities of treatment
title_full On the prevalence of vernal keratoconjunctivitis and current possibilities of treatment
title_fullStr On the prevalence of vernal keratoconjunctivitis and current possibilities of treatment
title_full_unstemmed On the prevalence of vernal keratoconjunctivitis and current possibilities of treatment
title_short On the prevalence of vernal keratoconjunctivitis and current possibilities of treatment
title_sort on the prevalence of vernal keratoconjunctivitis and current possibilities of treatment
topic весенний кератоконъюнктивит
распространенность
патогенез
лечение
vernal keratoconjunctivitis
prevalence
pathogenesis
treatment
url https://roj.igb.ru/jour/article/view/126
work_keys_str_mv AT vvbrzheskiy ontheprevalenceofvernalkeratoconjunctivitisandcurrentpossibilitiesoftreatment